As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback